These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 25159681)
21. Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction. Anderegg MC; Lagarde SM; Jagadesham VP; Gisbertz SS; Immanuel A; Meijer SL; Hulshof MC; Bergman JJ; van Laarhoven HW; Griffin SM; van Berge Henegouwen MI Ann Surg; 2016 Nov; 264(5):847-853. PubMed ID: 27429034 [TBL] [Abstract][Full Text] [Related]
22. The prognostic significance of tumor ploidy and pathology in adenocarcinoma of the esophagogastric junction. Schneeberger AL; Finley RJ; Troster M; Lohmann R; Keeney M; Inculet RI Cancer; 1990 Mar; 65(5):1206-10. PubMed ID: 2302668 [TBL] [Abstract][Full Text] [Related]
23. Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome. Barbour AP; Rizk NP; Gonen M; Tang L; Bains MS; Rusch VW; Coit DG; Brennan MF Ann Surg Oncol; 2007 Feb; 14(2):306-16. PubMed ID: 17091329 [TBL] [Abstract][Full Text] [Related]
24. Impact of lower mediastinal lymphadenectomy for the treatment of esophagogastric junction carcinoma. Hosoda K; Yamashita K; Katada N; Moriya H; Mieno H; Sakuramoto S; Kikuchi S; Watanabe M Anticancer Res; 2015 Jan; 35(1):445-56. PubMed ID: 25550586 [TBL] [Abstract][Full Text] [Related]
25. Comparison between site N-category and number N-category for nodal staging in carcinoma of the gastroesophageal junction: our experience and literature review. Aurello P; D'Angelo F; Nigri G; Bellagamba R; Cicchini C; Ruzzetti R; Ramacciato G Am Surg; 2006 Feb; 72(2):118-23. PubMed ID: 16536239 [TBL] [Abstract][Full Text] [Related]
26. Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer. Kamai T; Shirataki H; Nakanishi K; Furuya N; Kambara T; Abe H; Oyama T; Yoshida K BMC Cancer; 2010 Apr; 10():164. PubMed ID: 20426825 [TBL] [Abstract][Full Text] [Related]
27. Comparison of prognostic compatibility between seventh AJCC/TNM of the esophagus and 14th JCGC staging systems in Siewert type II adenocarcinoma. Kawaguchi T; Komatsu S; Ichikawa D; Kubota T; Okamoto K; Shiozaki A; Fujiwara H; Konishi H; Morimura R; Murayama Y; Kuriu Y; Ikoma H; Nakanishi M; Sakakura C; Otsuji E Anticancer Res; 2013 Aug; 33(8):3461-5. PubMed ID: 23898120 [TBL] [Abstract][Full Text] [Related]
28. Identification of the distinct genomic features in gastroesophageal junction adenocarcinoma and its Siewert subtypes. Geng Q; Lao J; Zuo X; Chen S; Bei JX; Xu D J Pathol; 2020 Nov; 252(3):263-273. PubMed ID: 32715475 [TBL] [Abstract][Full Text] [Related]
29. Lymph node ratio-based staging system as an alternative to the current TNM staging system to assess outcome in adenocarcinoma of the esophagogastric junction after surgical resection. Zhang H; Shang X; Chen C; Gao Y; Xiao X; Tang P; Duan X; Yang M; Jiang H; Yu Z Oncotarget; 2016 Nov; 7(45):74337-74349. PubMed ID: 27517157 [TBL] [Abstract][Full Text] [Related]
30. Correlations of P21-activated kinase 1 expression to clinicopathological features of gastric carcinoma and patients' prognosis. Wang JX; Zhou YN; Zou SJ; Ren TW; Zhang ZY Chin J Cancer; 2010 Jul; 29(7):649-54. PubMed ID: 20591216 [TBL] [Abstract][Full Text] [Related]
31. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478 [TBL] [Abstract][Full Text] [Related]
32. Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction. Hu X; Wu L; Liu B; Chen K Front Immunol; 2021; 12():651056. PubMed ID: 34122409 [TBL] [Abstract][Full Text] [Related]
33. [Adenocarcinoma of the esophagogastric junction: association with Barrett esophagus and gastroesophageal reflux--surgical results in 122 patients]. Schumpelick V; Dreuw B; Ophoff K; Fass J Leber Magen Darm; 1996 Mar; 26(2):75-6, 79-80, 83-6. PubMed ID: 8684248 [TBL] [Abstract][Full Text] [Related]
34. Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction. Schurr PG; Yekebas EF; Kaifi JT; Lasch S; Strate T; Kutup A; Cataldegirmen G; Bubenheim M; Pantel K; Izbicki JR J Surg Oncol; 2006 Sep; 94(4):307-15. PubMed ID: 16917878 [TBL] [Abstract][Full Text] [Related]
35. Topographical distribution of lymph node metastasis in adenocarcinoma of the gastroesophageal junction. Mönig SP; Baldus SE; Zirbes TK; Collet PH; Schröder W; Schneider PM; Dienes HP; Hölscher AH Hepatogastroenterology; 2002; 49(44):419-22. PubMed ID: 11995464 [TBL] [Abstract][Full Text] [Related]
36. [Clinical and pathological prognostic factors for cancers of the esophagogastric junction]. Schmidt SC; Schlechtweg N; Veltzke-Schlieker W; Thuss-Patience P; Pratschke J; Neuhaus P; Schumacher G Zentralbl Chir; 2009 Sep; 134(5):455-61. PubMed ID: 19757346 [TBL] [Abstract][Full Text] [Related]
37. Combination of preoperative platelet/lymphocyte and neutrophil/lymphocyte rates and tumor-related factors to predict lymph node metastasis in patients with gastric cancer. Pang W; Lou N; Jin C; Hu C; Arvine C; Zhu G; Shen X Eur J Gastroenterol Hepatol; 2016 May; 28(5):493-502. PubMed ID: 26854795 [TBL] [Abstract][Full Text] [Related]
39. Screening and clinical significance of lymph node metastasis-related genes within esophagogastric junction adenocarcinoma. Han R; Chen G; Li M; Peng ZM; Xu L Cancer Med; 2021 Aug; 10(15):5088-5100. PubMed ID: 34152098 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic approaches to gastroesophageal junction adenocarcinomas. Blom RL; Bogush T; Brücher BL; Chang AC; Davydov M; Dudko E; Leong T; Polotsky B; Swanson PE; van Rossum PS; Ruurda JP; Sagaert X; Tjulandin S; Schraepen MC; Sosef MN; van Hillegersberg R Ann N Y Acad Sci; 2014 Sep; 1325():197-210. PubMed ID: 25266026 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]